H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on ADMA Biologics to $4.50 from $4 and keeps a Buy rating on the shares after the company increased 2022 revenue guidance.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADMA:
- ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®
- ADMA Biologics announces FDA approval for storage of ASCENIV, BIVIGAM
- Biotech Alert: Searches spiking for these stocks today
- ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- ADMA Biologics 21M share Spot Secondary priced at $2.86